298 related articles for article (PubMed ID: 23637579)
1. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.
Palmer SC; Nistor I; Craig JC; Pellegrini F; Messa P; Tonelli M; Covic A; Strippoli GF
PLoS Med; 2013; 10(4):e1001436. PubMed ID: 23637579
[TBL] [Abstract][Full Text] [Related]
2. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.
Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L
Ren Fail; 2016 Jul; 38(6):857-74. PubMed ID: 27137817
[TBL] [Abstract][Full Text] [Related]
5. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis.
Cohen JB; Gordon CE; Balk EM; Francis JM
Transplantation; 2012 Nov; 94(10):1041-8. PubMed ID: 23069843
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
Liu Y; Yang Q; Chen G; Zhou T
Curr Pharm Des; 2022; 28(40):3289-3304. PubMed ID: 36305135
[TBL] [Abstract][Full Text] [Related]
9. Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital.
Sin HY
J Clin Pharm Ther; 2017 Oct; 42(5):607-614. PubMed ID: 28585333
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
12. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
Palmer SC; Teixeira-Pinto A; Saglimbene V; Craig JC; Macaskill P; Tonelli M; de Berardis G; Ruospo M; Strippoli GF
Am J Kidney Dis; 2015 Dec; 66(6):962-71. PubMed ID: 26003472
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Fukagawa M; Shimazaki R; Akizawa T;
Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
[TBL] [Abstract][Full Text] [Related]
14. Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.
Chen L; Wang K; Yu S; Lai L; Zhang X; Yuan J; Duan W
Ren Fail; 2016 Aug; 38(7):1050-8. PubMed ID: 27198474
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M
Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878
[TBL] [Abstract][Full Text] [Related]
16. Dialysis: Effect of cinacalcet on survival--the saga continues.
Komaba H; Fukagawa M
Nat Rev Nephrol; 2013 Aug; 9(8):435-6. PubMed ID: 23820810
[No Abstract] [Full Text] [Related]
17. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
[TBL] [Abstract][Full Text] [Related]
18. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.
Guerra R; Auyanet I; Fernández EJ; Pérez MÁ; Bosch E; Ramírez A; Suria S; Checa MD
J Nephrol; 2011; 24(1):78-82. PubMed ID: 20437396
[TBL] [Abstract][Full Text] [Related]
19. Development of evocalcet for unmet needs among calcimimetic agents.
Hamano N; Endo Y; Kawata T; Fukagawa M
Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
